Dr. Meyerowitz highlighted that the clade I variant of mpox is concerning due to higher mortality rates, ranging from 1% to 10%, compared to clade II's low rates.
The WHO's declaration of a public health emergency is largely driven by the emergence of clade I, which indicates a significant change in transmission patterns and potential severity.
Ongoing research on the antiviral TPOXX suggests a mortality rate of 1.7% for clade I, which is reassuring, but still indicates a level of risk.
Health officials are monitoring clusters, particularly in New York, showing that while clade II cases have declined, they haven't completely disappeared, necessitating continued vigilance.
[
Collection
]
[
|
...
]